Diagnostic and prognostic utility of serum β-synuclein in Alzheimer's disease: a longitudinal cohort study.

J Prev Alzheimers Dis · 2026 · PMC12964294 · PMID 41763014

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Both biomarkers showed a trend of progressive increase from CN A− to CN A+, MCI A+, and AD A+, but the group differences were more pronounced for serum β-synuclein.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.